AND EXCHANGE COMMISSION
to Section 13 or 15(d) of The Securities Exchange Act of 1934
of report (Date of earliest event reported) February 19, 2020
Name of Registrant as Specified in its Charter)
or other jurisdiction
Hanagar Street, Hod Hasharon, Israel
of principal executive offices)
telephone number, including area code: +(972) 72-260-0536
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act|
material pursuant to Rule 14a-12 under the Exchange Act|
communications pursuant to Rule 14d-2(b) under the Exchange Act|
communications pursuant to Rule 13e-4(c) under the Exchange Act|
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company ☒
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
8.01 Other Events.
February 19, 2020, Wize Pharma, Inc. (the “Company”) closed its previously
announced transactions, whereby (A) (i) the Company sold 37% of future revenues (if any)
from its L02A-based products to Bonus BioGroup Ltd. (“Bonus”), an Israeli company whose ordinary shares are traded
on the Tel Aviv Stock Exchange (“TASE”), and invested $7.4 million in Bonus and (ii) in consideration therefor, Bonus
issued to Wize new ordinary shares of Bonus in a number equal to $16.4 million divided by a purchase price per share of NIS 0.50,
and (B) the Company issued an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value
$0.001 per share, of the Company, for a purchase price of $1,000 per share, for aggregate gross proceeds of $7.5 million.
For additional details, see the Current Report on Form 8-K filed by the Company on January 15, 2020, which is incorporated herein
copy of the press release announcing the closing of the transactions is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. Exhibit 99.1 contains forward-looking statements, and includes cautionary statements
identifying important factors that could cause actual results to differ materially from those anticipated.
9.01. Financial Statements and Exhibits.
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
February 20, 2020